Resistance to azole antifungals is a growing concern in clinical settings. The mechanisms of resistance include mutations in the CYP51 gene, overexpression of efflux pumps, and alterations in membrane composition. These changes can reduce the efficacy of azole drugs, necessitating higher doses or alternative treatments, which may increase the risk of toxicity.
